- Home
- DYN
as 03-28-2025 4:00pm EST
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $47.73 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.72 - $47.45 | Next Earning Date: | 05-01-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | DYN | Chief Commercial Officer | Mar 13 '25 | Sell | $12.12 | 143 | $1,733.16 | 96,057 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 11 '25 | Sell | $11.38 | 1,343 | $15,283.34 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 11 '25 | Sell | $11.38 | 2,153 | $24,501.14 | 195,840 | |
| Cox John | DYN | CEO & President | Mar 5 '25 | Sell | $11.83 | 4,061 | $48,041.63 | 146,239 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 5 '25 | Sell | $11.83 | 917 | $10,848.11 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 5 '25 | Sell | $11.83 | 1,094 | $12,942.02 | 195,840 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Feb 18 '25 | Sell | $13.95 | 2,488 | $34,707.60 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Feb 18 '25 | Sell | $13.95 | 2,598 | $36,242.10 | 195,840 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Sector Update: Health Care Stocks Steady Premarket Friday
MT Newswires
11 days ago
Dyne Therapeutics Names Erick Lucera as CFO
GlobeNewswire
11 days ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
GlobeNewswire
11 days ago
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
MT Newswires
14 days ago
Sector Update: Health Care Stocks Decline Premarket Monday
MT Newswires
14 days ago
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
GlobeNewswire
15 days ago
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
Benzinga
19 days ago
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.